All In Biotech

Drug Trial Radar · NCT06930885

Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease: The EPOCA Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 7,713 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

7,713

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

May 2031

Study completion May 2031

Sponsor

Lead sponsor
Hospital do CoracaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.

Conditions

  • Atherothrombotic Diseases
  • Atherosclerotic Cardiovascular Disease (ASCVD)

Interventions

  • Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)Drug

    Cardiovascular Polypill contains Valsartan, Atorvastatin, Aspirin 1. Valsartan 160 mg + Atorvastatin 40 mg + Aspirin 100 mg or 2. Valsartan 160 mg + Atorvastatin 80 mg + Aspirin 100 mg or 3. Valsartan 320 mg + Atorvastatin 40 mg + Aspirin 100 mg or 4. Valsartan 320 mg + Atorvastatin 80 mg + Aspirin100 mg or 5. Valsartan 80 mg + Atorvastatin 40 mg + Aspirin 100 mg or 6. Valsartan 80 mg + Atorvastatin 80 mg + Aspirin 100 mg or 7. Valsartan 80 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 8. Valsartan 160 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 9. Valsartan 320 mg + Atorvastatin 20 mg + Aspirin 100 mg\* * The use of these formulations of the cardiovascular polypill will be restricted to cases of Statin-Related Muscle Symptoms (SRMS)

  • Colchicine 0.5 mgDrug

    Colchicine 0.5 mg once daily

  • Usual Care GroupDrug

    Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the guidelines. Drugs and doses will be left at the discretion of the treating physicians.

  • Colchicine-placebo 0.5 mgDrug

    Matching Colchicine-placebo 0.5 mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary efficacy endpoint: Major adverse cardiovascular and limb events (MACLE)Time frame: Through study completion, an estimated average of 3 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Centro de Pesquisas Clínicas Dr. Marco Mota

    Maceió, Alabama, Brazil · Recruiting

  • Secretária da Saúde do Estado do Ceará - Hospital de Messejana Dr. Carlos Alberto Studart Gomes

    Messejana, Ceará, Brazil · Recruiting

  • Empresa Brasileira de Serviços Hospitalares - EBSERCH - Hospital de Ensino Dr. Washington Antônio de Barros- HU-UNIVASF

    Petrolina, Pernambuco, Brazil · Recruiting

  • Centro de Pesquisa Cardiolima

    Teresina, Piauí, Brazil · Recruiting

  • Fundação Técnico Educacional Souza Marques

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Fundação Universitária de Cardiologia - ICFUC

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Instituto de Pesquisa e Ensino em Saúde - IPES

    Porto Velho, Rondônia, Brazil · Recruiting

  • CMEP - Centro Multidisciplinar de Ensino especializado e Pesquisa

    Joinville, Santa Catarina, Brazil · Recruiting

  • Hospital Universitário São Francisco na Providência de Deus

    Bragança Paulista, São Paulo, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina São José do Rio Preto

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • CIPES - Centro Internacional de Pesquisa Clínica

    São José dos Campos, São Paulo, Brazil · Recruiting

  • Hcor

    São Paulo, São Paulo, Brazil · Recruiting

  • Centro de Pesquisa Cetrus

    São Paulo, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.